Marinus Pharmaceuticals Inc (MRNS) 8.99 $MRNS
3 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Apr 16, 1:18PM CDT
These under-$10 stocks are within range of triggering breakout trades.
FULL: 3.71 (unch), MRNS: 8.99 (-0.68), GSI: 1.02 (+0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 8:11AM CDT
YGE: 1.87 (-0.10), AIRM: 47.47 (+1.42), RMGN: 1.45 (+0.09), KRFT: 88.25 (-0.22), FXCM: 2.13 (+0.02), LL: 33.86 (+0.50), BLRX: 2.12 (unch), ENLK: 25.74 (unch), KFX: 11.02 (-0.01), AMSC: 10.40 (+1.20), MRNS: 8.99 (-0.68), NVAX: 8.51 (+0.09), NSM: 25.29 (+0.06), VBLT: 4.37 (-0.08), APOL: 17.64 (+0.11), LXK: 44.24 (+1.17)
Marinus Pharma's ganaxolone an Orphan Drug for female epilepsy
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 7:13AM CDT
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation in PCDH19 Female Epilepsy
GlobeNewswire - Wed Mar 25, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, for the treatment of protocadherin 19 gene (PCDH19) female epilepsy. Marinus is currently conducting a Phase 2 clinical trial evaluating the safety and efficacy of ganaxolone as adjunctive therapy for uncontrolled seizures in PCDH19 female pediatric epilepsy, and expects initial data in 2015.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals to Participate in Future Leaders in the Biotech Industry Conference
GlobeNewswire - Mon Mar 16, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present at the BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 10:00 a.m. ET. The conference will take place at the Millennium Broadway Hotel in New York.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals EPS of -$2.17
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:37PM CDT
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals Provides Business Update and Reports Year End 2014 Financial Results
GlobeNewswire - Thu Mar 12, 3:00PM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, today provided a business update and announced its financial results for the year ended December 31, 2014.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals (MRNS) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 7:35AM CST
Marinus Pharmaceuticals saw a big move last session, as the company’s shares fell by 5% which continued the downtrend for the company
MRNS: 8.99 (-0.68), IG: 9.07 (+0.35)
Marinus Pharmaceuticals to Participate in Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 09, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced it will be participating in the Leerink Global Healthcare Conference on Thursday, February 12, 2015 at the Waldorf Astoria in New York.
MRNS: 8.99 (-0.68)
U.S. Congressman Patrick Meehan to Present Keynote Address at 22nd Annual Groundhog Investment Forum
Business Wire - Tue Feb 03, 9:15AM CST
Emerald Asset Management, Inc. has announced that U.S. Congressman Patrick Meehan will present the keynote address to the close the 22nd annual Groundhog Day Investment Forum on Thursday, February 5th in Philadelphia. Currently serving his third term in Congress, Congressman Meehan represents Pennsylvania's 7th Congressional District, serving on the influential House Ways and Means Committee, as well as the Committee on Ethics. In the 113th Congress, Meehan chaired the House Homeland Security Committee's Subcommittee on Cybersecurity. Meehan focused on protecting America's critical infrastructure -- our transportation, energy, financial and communications systems -- from cyberattack. "Cybersecurity is a critical issue for our nation and for every American company," said Emerald CEO Joseph E. Besecker. "We welcome Congressman Meehan and his are eager to hear about Washington's ongoing efforts to protect the Homeland, including our vital technology-related assets," he said. Among the investment themes for 2015 identified by Emerald is the growing attention to cybersecurity and companies that provide related services and solutions.
SFE: 18.59 (+0.32), CODI: 17.12 (-0.04), MATW: 50.74 (+0.08), CUBI: 25.30 (-0.10), SASR: 26.41 (+0.14), TREX: 51.48 (-0.49), SN: 14.18 (-0.30), RBPAA: 1.72 (unch), STON: 29.90 (-0.02), INO: 10.39 (-0.09), WTR: 26.85 (+0.01), ALNY: 118.00 (-2.70), STBA: 27.80 (+0.15), MRNS: 8.99 (-0.68), APOG: 52.89 (+0.69), KWR: 86.55 (+0.10), BMTC: 31.51 (+0.38), EPAM: 67.99 (-0.16), ACTA: 14.71 (+0.24), GSVC: 9.80 (unch)
Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone in PCDH19 Female Pediatric Epilepsy
GlobeNewswire - Tue Feb 03, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, announced that it has initiated a Phase 2 clinical trial with ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, in female children with epilepsy caused by a mutation of the protocadherin 19 gene (PCDH19). PCDH19 female pediatric epilepsy is a rare disease that is estimated to affect approximately 15,000-30,000 females in the U.S. and is characterized by onset of cluster seizures before age 5, cognitive and sensory impairment of varying degrees, and behavioral disturbances. There are currently no approved therapies for PCDH19 female pediatric epilepsy. The multicenter, open-label clinical trial is designed to evaluate the safety and efficacy of ganaxolone as adjunctive therapy for uncontrolled seizures in PCDH19 female pediatric epilepsy.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 6:35AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present at the 2015 BIO CEO and Investor Conference on Monday, February 9, 2015 at 10:30 a.m. ET. The conference will take place at the Waldorf Astoria in New York.
MRNS: 8.99 (-0.68)
Investment Industry to Gather in Philadelphia at 22nd Annual Groundhog Day Investment Forum
Business Wire - Thu Jan 29, 11:05AM CST
Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 22nd annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 5th at the Radisson Blu Warwick Hotel in Philadelphia, PA. "Each year we say that the investment year begins in earnest with our annual Forum," said Emerald CEO and Founder Joseph E. Besecker. "This year with increased market volatility and an uncertain economic outlook, hearing directly from corporate leaders and our team of analysts and portfolio managers is even more imperative," he said. Public company senior managers, investment portfolio managers and research analysts come together to review 2014 and provide their initial outlook to 2015 and beyond. This year's Forum will include sessions focusing on cyber security, advances in biotechnology, community and regional banks, income-oriented and alternative investments and ongoing innovations by corporate America generating potential investment opportunities.
SFE: 18.59 (+0.32), MATW: 50.74 (+0.08), CUBI: 25.30 (-0.10), SASR: 26.41 (+0.14), TREX: 51.48 (-0.49), SN: 14.18 (-0.30), RBPAA: 1.72 (unch), STON: 29.90 (-0.02), INO: 10.39 (-0.09), WTR: 26.85 (+0.01), ALNY: 118.00 (-2.70), STBA: 27.80 (+0.15), MRNS: 8.99 (-0.68), APOG: 52.89 (+0.69), KWR: 86.55 (+0.10), BMTC: 31.51 (+0.38), EPAM: 67.99 (-0.16), ACTA: 14.71 (+0.24), GSVC: 9.80 (unch)
Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
GlobeNewswire - Tue Jan 27, 6:33AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced it will participate in the Canaccord Genuity 2015 Rare Disease, BioPharma One-on-One Day, on Tuesday, February 3, 2015 at the Omni Berkshire Place in New York.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals Hires Dr. Albena Patroneva as Chief Medical Officer
GlobeNewswire - Wed Jan 07, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has retained Albena Patroneva, MD as Chief Medical Officer. Dr. Patroneva brings close to 20 years of experience spanning across research, drug development, clinical, regulatory and commercialization activities focused in neurology with large pharmaceutical companies, including AstraZeneca, Wyeth and Takeda. As Chief Medical Officer, Dr. Patroneva will oversee Marinus's clinical programs in epilepsy and pediatric orphan indications with its neurosteroid, ganaxolone.
MRNS: 8.99 (-0.68)
Marinus (MRNS) Shows Strength: Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:39AM CST
Marinus Pharmaceuticals, Inc. (MRNS) was a big mover last session with its shares rising nearly 9% on the day.
LCI: 66.45 (-0.28), MRNS: 8.99 (-0.68)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 43.23 (-0.43), TNXP: 6.73 (+0.21), MRNS: 8.99 (-0.68), CPRX: 4.54 (-0.02), VNDA: 9.99 (-0.25), ITCI: 23.78 (-0.81), OMER: 24.41 (-0.15)
Fragile X Syndrome Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014
PRWeb - Sun Dec 07, 1:31PM CST
The report "Fragile X Syndrome Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. Fragile X Syndrome is the most common inherited form of mental problems and this disease caused by changes in a single X. Complete Report is Available @ http://www.rnrmarketresearch.com/fragile-x-sy...eport.html .
MRNS: 8.99 (-0.68), PRTK: 28.96 (+0.61)
Marinus Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 03, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present at the 2014 Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 9:10 a.m. ET. The conference will take place at the Crowne Plaza Hotel in New York.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals beats by $0.23
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:44AM CST
MRNS: 8.99 (-0.68)
3 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Apr 16, 1:18PM CDT
These under-$10 stocks are within range of triggering breakout trades.
FULL: 3.71 (unch), MRNS: 8.99 (-0.68), GSI: 1.02 (+0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 8:11AM CDT
YGE: 1.87 (-0.10), AIRM: 47.47 (+1.42), RMGN: 1.45 (+0.09), KRFT: 88.25 (-0.22), FXCM: 2.13 (+0.02), LL: 33.86 (+0.50), BLRX: 2.12 (unch), ENLK: 25.74 (unch), KFX: 11.02 (-0.01), AMSC: 10.40 (+1.20), MRNS: 8.99 (-0.68), NVAX: 8.51 (+0.09), NSM: 25.29 (+0.06), VBLT: 4.37 (-0.08), APOL: 17.64 (+0.11), LXK: 44.24 (+1.17)
Marinus Pharma's ganaxolone an Orphan Drug for female epilepsy
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 7:13AM CDT
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation in PCDH19 Female Epilepsy
GlobeNewswire - Wed Mar 25, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, for the treatment of protocadherin 19 gene (PCDH19) female epilepsy. Marinus is currently conducting a Phase 2 clinical trial evaluating the safety and efficacy of ganaxolone as adjunctive therapy for uncontrolled seizures in PCDH19 female pediatric epilepsy, and expects initial data in 2015.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals to Participate in Future Leaders in the Biotech Industry Conference
GlobeNewswire - Mon Mar 16, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present at the BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 10:00 a.m. ET. The conference will take place at the Millennium Broadway Hotel in New York.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals EPS of -$2.17
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:37PM CDT
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals Provides Business Update and Reports Year End 2014 Financial Results
GlobeNewswire - Thu Mar 12, 3:00PM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, today provided a business update and announced its financial results for the year ended December 31, 2014.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals (MRNS) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 7:35AM CST
Marinus Pharmaceuticals saw a big move last session, as the company’s shares fell by 5% which continued the downtrend for the company
MRNS: 8.99 (-0.68), IG: 9.07 (+0.35)
Marinus Pharmaceuticals to Participate in Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 09, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced it will be participating in the Leerink Global Healthcare Conference on Thursday, February 12, 2015 at the Waldorf Astoria in New York.
MRNS: 8.99 (-0.68)
U.S. Congressman Patrick Meehan to Present Keynote Address at 22nd Annual Groundhog Investment Forum
Business Wire - Tue Feb 03, 9:15AM CST
Emerald Asset Management, Inc. has announced that U.S. Congressman Patrick Meehan will present the keynote address to the close the 22nd annual Groundhog Day Investment Forum on Thursday, February 5th in Philadelphia. Currently serving his third term in Congress, Congressman Meehan represents Pennsylvania's 7th Congressional District, serving on the influential House Ways and Means Committee, as well as the Committee on Ethics. In the 113th Congress, Meehan chaired the House Homeland Security Committee's Subcommittee on Cybersecurity. Meehan focused on protecting America's critical infrastructure -- our transportation, energy, financial and communications systems -- from cyberattack. "Cybersecurity is a critical issue for our nation and for every American company," said Emerald CEO Joseph E. Besecker. "We welcome Congressman Meehan and his are eager to hear about Washington's ongoing efforts to protect the Homeland, including our vital technology-related assets," he said. Among the investment themes for 2015 identified by Emerald is the growing attention to cybersecurity and companies that provide related services and solutions.
SFE: 18.59 (+0.32), CODI: 17.12 (-0.04), MATW: 50.74 (+0.08), CUBI: 25.30 (-0.10), SASR: 26.41 (+0.14), TREX: 51.48 (-0.49), SN: 14.18 (-0.30), RBPAA: 1.72 (unch), STON: 29.90 (-0.02), INO: 10.39 (-0.09), WTR: 26.85 (+0.01), ALNY: 118.00 (-2.70), STBA: 27.80 (+0.15), MRNS: 8.99 (-0.68), APOG: 52.89 (+0.69), KWR: 86.55 (+0.10), BMTC: 31.51 (+0.38), EPAM: 67.99 (-0.16), ACTA: 14.71 (+0.24), GSVC: 9.80 (unch)
Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone in PCDH19 Female Pediatric Epilepsy
GlobeNewswire - Tue Feb 03, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, announced that it has initiated a Phase 2 clinical trial with ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, in female children with epilepsy caused by a mutation of the protocadherin 19 gene (PCDH19). PCDH19 female pediatric epilepsy is a rare disease that is estimated to affect approximately 15,000-30,000 females in the U.S. and is characterized by onset of cluster seizures before age 5, cognitive and sensory impairment of varying degrees, and behavioral disturbances. There are currently no approved therapies for PCDH19 female pediatric epilepsy. The multicenter, open-label clinical trial is designed to evaluate the safety and efficacy of ganaxolone as adjunctive therapy for uncontrolled seizures in PCDH19 female pediatric epilepsy.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 6:35AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present at the 2015 BIO CEO and Investor Conference on Monday, February 9, 2015 at 10:30 a.m. ET. The conference will take place at the Waldorf Astoria in New York.
MRNS: 8.99 (-0.68)
Investment Industry to Gather in Philadelphia at 22nd Annual Groundhog Day Investment Forum
Business Wire - Thu Jan 29, 11:05AM CST
Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 22nd annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 5th at the Radisson Blu Warwick Hotel in Philadelphia, PA. "Each year we say that the investment year begins in earnest with our annual Forum," said Emerald CEO and Founder Joseph E. Besecker. "This year with increased market volatility and an uncertain economic outlook, hearing directly from corporate leaders and our team of analysts and portfolio managers is even more imperative," he said. Public company senior managers, investment portfolio managers and research analysts come together to review 2014 and provide their initial outlook to 2015 and beyond. This year's Forum will include sessions focusing on cyber security, advances in biotechnology, community and regional banks, income-oriented and alternative investments and ongoing innovations by corporate America generating potential investment opportunities.
SFE: 18.59 (+0.32), MATW: 50.74 (+0.08), CUBI: 25.30 (-0.10), SASR: 26.41 (+0.14), TREX: 51.48 (-0.49), SN: 14.18 (-0.30), RBPAA: 1.72 (unch), STON: 29.90 (-0.02), INO: 10.39 (-0.09), WTR: 26.85 (+0.01), ALNY: 118.00 (-2.70), STBA: 27.80 (+0.15), MRNS: 8.99 (-0.68), APOG: 52.89 (+0.69), KWR: 86.55 (+0.10), BMTC: 31.51 (+0.38), EPAM: 67.99 (-0.16), ACTA: 14.71 (+0.24), GSVC: 9.80 (unch)
Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
GlobeNewswire - Tue Jan 27, 6:33AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced it will participate in the Canaccord Genuity 2015 Rare Disease, BioPharma One-on-One Day, on Tuesday, February 3, 2015 at the Omni Berkshire Place in New York.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals Hires Dr. Albena Patroneva as Chief Medical Officer
GlobeNewswire - Wed Jan 07, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has retained Albena Patroneva, MD as Chief Medical Officer. Dr. Patroneva brings close to 20 years of experience spanning across research, drug development, clinical, regulatory and commercialization activities focused in neurology with large pharmaceutical companies, including AstraZeneca, Wyeth and Takeda. As Chief Medical Officer, Dr. Patroneva will oversee Marinus's clinical programs in epilepsy and pediatric orphan indications with its neurosteroid, ganaxolone.
MRNS: 8.99 (-0.68)
Marinus (MRNS) Shows Strength: Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:39AM CST
Marinus Pharmaceuticals, Inc. (MRNS) was a big mover last session with its shares rising nearly 9% on the day.
LCI: 66.45 (-0.28), MRNS: 8.99 (-0.68)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 43.23 (-0.43), TNXP: 6.73 (+0.21), MRNS: 8.99 (-0.68), CPRX: 4.54 (-0.02), VNDA: 9.99 (-0.25), ITCI: 23.78 (-0.81), OMER: 24.41 (-0.15)
Fragile X Syndrome Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014
PRWeb - Sun Dec 07, 1:31PM CST
The report "Fragile X Syndrome Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. Fragile X Syndrome is the most common inherited form of mental problems and this disease caused by changes in a single X. Complete Report is Available @ http://www.rnrmarketresearch.com/fragile-x-sy...eport.html .
MRNS: 8.99 (-0.68), PRTK: 28.96 (+0.61)
Marinus Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 03, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present at the 2014 Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 9:10 a.m. ET. The conference will take place at the Crowne Plaza Hotel in New York.
MRNS: 8.99 (-0.68)
Marinus Pharmaceuticals beats by $0.23
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:44AM CST
MRNS: 8.99 (-0.68)
